Last week, Oscar Health Inc. (NYSE:OSCR) reported second-quarter revenue of approximately $2.86 billion, compared to $2.2 billion in the same period the previous year, missing the consensus estimate of $2.91 billion.
The sales increase was primarily driven by higher membership, partially offset by an increase in net risk adjustment transfer accrual.
The healthcare technology company reported a loss of 89 cents per share, missing the consensus estimate of 86 cents.
The medical loss ratio was 91.1% for the second quarter of 2025, compared to 79.0% for the same quarter in 2024, primarily driven by an increase in average market morbidity that led to a higher net risk adjustment transfer accrual.
Guidance: Oscar Health reaffirms its fiscal 2025 sales guidance of $12 billion to $12.2 billion, compared to the Wall Street estimate of $11.32 billion.
Also Read: Oscar Health Well-Positioned To Manage Market Reset, Eyes Profitability In …